Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP)

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Coronary slow flow phenomenon (CSFP) is a microvascular disorder with significant morbidity and limited treatment options.
• Endothelial dysfunction is a key factor in the development of CSFP.
• Telmisartan (TMST), an antihypertensive drug, has demonstrated potential in improving vascular endothelial function.

Purpose of the Study:

• To investigate the therapeutic effects of Telmisartan (TMST) on endothelial dysfunction in patients with CSFP.
• To evaluate TMST's impact on endothelial-dependent vasodilation, nitric oxide, adiponectin, and endothelin-1 levels.

Main Methods:

• Patients with CSFP received TMST for 3 months.
• Measurements included flow-mediated vasodilation, serum nitric oxide, adiponectin, and endothelin-1 levels before and after treatment.
• Vasodilator response to acetylcholine (Ach) was assessed post-treatment.
• Molecular analysis examined changes in specific gene and protein expressions.

Main Results:

• TMST treatment significantly improved flow-mediated vasodilation, nitric oxide, and adiponectin levels (P < .01).
• Endothelin-1 levels decreased significantly after TMST treatment (P < .01).
• TMST enhanced vasodilator response to Ach and modulated key molecular pathways, including HGF, MET, PPARγ, p-JNK1/2, MAPK, and NF-κB.

Conclusions:

• Telmisartan (TMST) effectively ameliorates endothelial dysfunction in coronary slow flow phenomenon (CSFP).
• TMST demonstrates significant potential as a novel therapeutic agent for managing CSFP.
• The findings suggest TMST's beneficial role in improving vascular endothelial function in CSFP patients.